Immuneering Corp

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Jefferies Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Immuneering to Present at the Jefferies Healthcare Conference

Immuneering Corporation (IMRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.49 per share a year ago.

Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates

- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting -

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) (“Immuneering”), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of $11.00 per share. The gross proceeds from the offering are expected be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All shares in the offering will be offered by Immuneering.

Immuneering Announces $30 Million Underwritten Offering

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced positive initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 trial of IMM-1-104 (NCT05585320), which are being shared today in a poster presentation titled “Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors” (abstract #4265) at the American Association for Cancer Research (AACR) annual meeting.

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains?

- Investor call to be held at 9:00 a.m. ET on April 18, 2023 - - Investor call to be held at 9:00 a.m. ET on April 18, 2023 -

Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade

Immuneering is a clinical-stage biopharmaceutical that focuses on oncology therapies. The company's lead therapy is in a phase 1/2a trial.

Why Shares of Immuneering Jumped This Week

Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?

Demonstrates ability to identify patient populations that may benefit from IMM-1-104 treatment

Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

The average of price targets set by Wall Street analysts indicates a potential upside of 210.2% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect?

Immuneering Corporation (NASDAQ:IMRX ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Laurence Watts - Investor Relations, Gilmartin Group Benjamin Zeskind - President and Chief Executive Officer Brett Hall - Chief Scientific Officer Scott Barrett - Chief Medical Officer Mallory Morales - Vice President of Finance, Treasurer Conference Call Participants Swapnil Malekar - Piper Sandler Jeffrey Hung - Morgan Stanley Mark Breidenbach - Oppenheimer & Co. Inc. Michael Schmidt - Guggenheim Partners Operator Welcome to the Immuneering Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Immuneering Corporation (IMRX) Q4 2022 Earnings Call Transcript

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 13.79% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates

First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation

Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation

Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will participate in two March investor conferences to share commentary around the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Immuneering Announces Participation in March Investor Conferences

Management to host conference call on Monday, March 6 at 4:30 p.m. ET Management to host conference call on Monday, March 6 at 4:30 p.m. ET

Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical stage biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activating events, today announced that management will present at Guggenheim's 2023 Oncology Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.

Immuneering To Present at Guggenheim 2023 Oncology Conference

Affimed

BioAtla, Inc

Eiger BioPharmaceuticals

Gracell Biotechnologies

Nkarta, Inc.

Instil Bio

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

7 Cheap But Risky Biotech Stocks

IMM-1-104 being tested in first all-comers RAS clinical trial believed to be conducted to date

Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of -2.08% and 92.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates

Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter

News for Immuneering Corp Stock (IMRX)